Dare Bioscience, INC. (DARE) — 8-K Filings

All 8-K filings from Dare Bioscience, INC.. Browse 32 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (32)

8-K Filing — Apr 22, 2026
8-K Filing — Dec 1, 2025
Dare Bioscience Files 8-K on Financials — Nov 13, 2025 Risk: low
On November 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
Dare Bioscience (DARE) Files 8-K Report — Sep 2, 2025 Risk: low
On September 2, 2025, Dare Bioscience, Inc. (DARE) filed an 8-K report. The filing indicates that the company's common stock is registered on the Nasdaq Capital
Dare Bioscience, Inc. Files 8-K Report — Aug 14, 2025 Risk: low
On August 14, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 3655 Nobel Drive, S
Dare Bioscience Files 8-K Report — Jul 25, 2025 Risk: low
On July 25, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transa
Dare Bioscience Files 8-K for Unspecified Event — Jul 21, 2025 Risk: medium
On July 18, 2025, Dare Bioscience, Inc. filed an 8-K report detailing an 'Other Event'. The filing does not provide specific details about the event itself, but
Dare Bioscience Files 8-K Report — Jul 14, 2025 Risk: low
On July 14, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regu
Dare Bioscience Files 8-K: Director Changes & Officer Compensation Updates — Jul 9, 2025 Risk: medium
On July 9, 2025, Dare Bioscience, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a ne
Dare Bioscience Files 8-K: Other Events — Jun 25, 2025 Risk: low
On June 25, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transa
8-K Filing — Jun 9, 2025
Dare Bioscience Files 8-K on Financials — May 13, 2025 Risk: low
On May 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
Dare Bioscience Files 8-K for Other Event — Apr 11, 2025 Risk: medium
On April 11, 2025, Dare Bioscience, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, bu
Dare Bioscience Files 8-K on Financials — Mar 31, 2025 Risk: low
Dare Bioscience, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
Dare Bioscience Faces Nasdaq Delisting Risk — Feb 14, 2025 Risk: medium
On February 13, 2025, Dare Bioscience, Inc. filed an 8-K report indicating a potential delisting from the Nasdaq Capital Market. The company received a deficien
Dare Bioscience Files 8-K: Reg FD & Financials — Feb 10, 2025 Risk: low
On February 10, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. T
8-K Filing — Jan 13, 2025
Dare Bioscience Files 8-K Report — Dec 16, 2024 Risk: low
On December 16, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
Dare Bioscience Files 8-K on Financials — Nov 14, 2024 Risk: medium
On November 14, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with
8-K Filing — Oct 25, 2024
Dare Bioscience Files 8-K with Material Agreement Details — Oct 23, 2024 Risk: medium
On October 23, 2024, Dare Bioscience, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and
Dare Bioscience Files 8-K: Material Agreement & Equity Sales — Oct 21, 2024 Risk: medium
On October 21, 2024, Dare Bioscience, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and
Dare Bioscience Files 8-K on Financials — Aug 12, 2024 Risk: low
On August 12, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
Dare Bioscience Closes $15M Public Offering — Jul 19, 2024 Risk: medium
On July 18, 2024, Dare Bioscience, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approxim
Dare Bioscience Secures $50M Financing from OrbiMed — Jun 27, 2024 Risk: medium
On June 21, 2024, Dare Bioscience, Inc. announced a strategic financing agreement with OrbiMed, a leading healthcare investment firm. The agreement includes a $
Dare Bioscience Holds Annual Stockholder Meeting — Jun 7, 2024 Risk: low
On June 5, 2024, Dare Bioscience, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on se
Dare Bioscience Files 8-K on Financials — May 14, 2024 Risk: low
On May 14, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well a
Dare Bioscience Enters Material Agreement, Faces Financial Obligation — Apr 30, 2024 Risk: medium
On April 29, 2024, Dare Bioscience, Inc. entered into a material definitive agreement related to the completion of an acquisition or disposition of assets. This
Dare Bioscience Files 8-K on Financials — Mar 28, 2024 Risk: low
On March 28, 2024, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, includi
Dare Bioscience Files Routine 8-K on Jan 26, 2024 — Jan 26, 2024
Dare Bioscience, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 23, 2024. This filing is a standard current report, indicati
Dare Bioscience Faces Nasdaq Delisting Risk Over Bid Price — Jan 19, 2024
Dare Bioscience, Inc. (DARE) reported on January 17, 2024, that it received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement
Dare Bioscience Files 8-K: Regulation FD Disclosure & Exhibits — Jan 8, 2024
Dare Bioscience, Inc. filed an 8-K on January 8, 2024, indicating a Regulation FD Disclosure and the filing of Financial Statements and Exhibits. This filing, u

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX